Sudarshan Pharma Industries CFO Manoj Lodha Resigns for Strategic Role Aug 18, 2025
More news about Sudarshan Pharma Industries
18Aug 25
Sudarshan Pharma Industries Posts Impressive Q1 Turnaround with ₹37 Crore Net Profit
Sudarshan Pharma Industries has reported a significant turnaround in Q1 financial performance. The company's net profit reached ₹37.00 crore, compared to a loss of ₹12.00 crore in the same quarter last year. Revenue grew by 40% to ₹140.00 crore from ₹100.00 crore year-over-year. EBITDA surged to ₹10.30 crore from ₹2.00 crore, with the EBITDA margin expanding to 7.22% from 1.94%. This strong performance across all key metrics indicates successful implementation of growth and profitability strategies.
Sudarshan Pharma Industries Limited has acquired Cibachem General Trading LLC, a Dubai-based company, as a wholly-owned subsidiary for Rs. 55.00 lakh. The acquisition involves 300 shares representing 100% of Cibachem's paid-up share capital. Cibachem, established in 2013, operates in general trading. Separately, Sudarshan Pharma's CFO, Mr. Manoj Lodha, has resigned effective August 5, 2025. The acquisition aims to expand Sudarshan Pharma's customer base in the Middle East region.
05Aug 25
Sudarshan Pharma Expands Middle East Presence with 100% Acquisition of Dubai-Based Cibachem General Trading
Sudarshan Pharma Industries Limited has acquired a 100% stake in Cibachem General Trading LLC, a Dubai-based company, for Rs. 55.00 lakh. The acquisition involves 300 equity shares of Cibachem, each with a face value of AED 1,000. Cibachem, established in 2013, focuses on general trading activities. This move aligns with Sudarshan Pharma's strategy to expand its presence in the Middle East market. The company also announced the resignation of Mr. Manoj Lodha as CFO, effective August 5, 2025.
20Jun 25
Sudarshan Pharma Approves ₹1,500 Crore Fundraising, Plans US Subsidiary
Sudarshan Pharma Industries Limited's board has approved a fundraising plan of up to ₹1,500 crore. The company also plans to establish a wholly-owned subsidiary, Sudarshan Industries LLC, in the United States. The new subsidiary will focus on manufacturing chemical products, producing pharmaceutical items, and trading in FMCG products. This move aims to expand the company's global presence and diversify its product portfolio.
13May 25
Sudarshan Pharma Industries Set to Acquire Cibachem Shares for ₹5.5 Crore
Sudarshan Pharma Industries has announced the acquisition of 300 shares of Cibachem for ₹5.5 crore. This strategic move aims to expand Sudarshan Pharma's portfolio and potentially strengthen its position in the pharmaceutical sector. The acquisition could indicate the company's intentions to diversify operations or enhance its existing product line.
Sudarshan Pharma Industries announced impressive financial results for H2 FY25, with net sales up 19% to ₹277.00 crore and net profit surging 43% to ₹7.00 crore year-over-year. For the full FY25, net sales increased 9% to ₹505.00 crore, while net profit grew 45% to ₹16.00 crore. The company's performance is attributed to its focus on expanding exports, boosting domestic sales of manufactured medicines, and enhancing profit margins from API reselling.
Sudarshan Pharma Industries Ltd reported a 52% increase in Q4 profit to ₹10.03 crore, with revenue rising 16.6% to ₹277.26 crore. For FY2025, total income reached ₹507.57 crore, up from ₹466.15 crore in FY2024. Net profit for the year increased to ₹15.96 crore from ₹11.46 crore. The company's EPS improved to ₹0.66, and its financial position strengthened with total assets at ₹402.41 crore. The debt-to-equity ratio stood at 1.30, and the interest coverage ratio improved to 2.65.
20Feb 25
Sudarshan Pharma Industries Expands Globally with New Polish Subsidiary
Sudarshan Pharma Industries Limited (SPIL) has approved the incorporation of a wholly-owned subsidiary in Poland, Sudarshan Pharma Poland Limited Liability Company. The new entity will be established with an investment of PLN 5,000 (approx. Rs. 1,50,000) and is set to engage in diverse operations including potato processing, chemical production, and pharmaceutical manufacturing and wholesaling. The subsidiary's incorporation, targeted for completion by April 30, 2025, marks SPIL's strategic entry into the European market and requires approval from the Reserve Bank of India under FEMA regulations.